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Purpose: Mitochondrial disease (MD) and Duchenne muscular dystrophy (DMD) are often associated 
with cardiomyopathy, but the myocardial variability has not been isolated to a specific characteristic. 
We evaluated the left ventricular (LV) mass by echocardiography to identify the general distribution and 
functional changes of the myocardium in patients with MD or DMD.
Methods: We retrospectively evaluated the echocardiographic data of 90 children with MD and 42 
with DMD. Using two-dimensional echocardiography, including time-motion (M) mode and Doppler 
measurements, we estimated the LV mass, ratio of early to late mitral filling velocities (E/A), ratio of 
early mitral filling velocity to early diastolic mitral annular velocity (E/Ea), stroke volume, and cardiac 
output. A “z score” was generated using the lambda-mu-sigma method to standardize the LV mass 
with respect to body size. 
Results: The LV mass-for-height z scores were significantly below normal in children with MD 
(–1.02±1.52, P<0.001) or DMD (–0.82±1.61, P=0.002), as were the LV mass-for-lean body-mass z 
scores. The body mass index (BMI)-for-age z scores were far below normal and were directly propor-
tional to the LV mass-for-height  z scores in both patients with MD (R=0.377, P<0.001) and those with DMD 
(R=0.330, P=0.033). The LV mass-for-height  z score correlated positively with the stroke volume index 
(R=0.462, P<0.001) and cardiac index (R=0.358, P<0.001).
Conclusion: LV myocardial atrophy is present in patients with MD and those with DMD and may be 
closely associated with low BMI. The insufficient LV mass for body size might indicate deterioration of 
systolic function in these patients.
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Mitochondrial disease (MD) arises from mutations within nuclear and mitochondrial 
genes, which control mitochondrial respiratory chain proteins1). These mutations may 
cause defects in oxidative phosphorylation. The brain, skeletal, and heart muscle are 
particularly vulnerable to defects in energy metabolism. Thus, mitochondrial encephalo­
myopathies and cardiomyopathies are commonly found in MD2). MD can develop at any 
age from infancy to adulthood. Childhood­onset MD is usually more aggressive than 
adult­onset MD3).
Duchenne muscular dystrophy (DMD) is the most common X­linked recessive hereditary 
neuromuscular disease. It is caused by a defect in the dystrophin gene product4). Dystrophin is 
expressed in the extracellular membrane of skeletal, cardiac and smooth muscle where it 
prevents injury to muscle fibers. A defect in dystrophin weakens muscle cells and results 
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in atrophic change depending on the amount of stresses5). DMD 
mainly affects boys and usually begins in early childhood, causing 
progressive weakness in proximal muscles and cardiac dys function 
by the teen years6).
Despite differences in pathologic processes, these two diseases 
exhibit similar features in children, such as progressive muscular 
weakness, growth failure and cardiac dysfunction. According to 
many researchers, cardiac involvement occurs in 20% of patients 
with MD and up to 90% of patients with DMD during childhood. 
Once a cardiomyopathy develops, it results in significant mortality 
in both groups of patients7,8). For these reasons, cardiologists have 
focused on the pathologic transformation of myocardium in af­
fected patients. However, some researchers suggested a loss of 
myocardium in the progression of DMD or paralyzed patients9,10). 
Thus, it is still worthy to investigate if myocardium has the varia­
bility within a specific characteristic, as skeletal muscle is worn 
down gradually. This process might result in either hypertrophy 
or reduction in patients with MD and DMD.
We can evaluate changes in myocardial structure by estimating 
left ventricular (LV) mass on a preferential basis with time­motion 
mode (M­mode) echocardiography. In adults, various indices 
have been introduced to normalize LV mass to body size with 
easy calculations such as dividing LV mass by height or body 
surface area (BSA). However, normalization of LV mass has not 
been achieved with the old methods in young children. This is 
pro bably because of the complex variables that influence ventri­
cular mass during normal development11). Our study introduces 
a latest method that scores LV mass and eliminates the impact of 
body size. We have investigated the transformation of LV structure 
and its influence on cardiac function using M­mode and Doppler 
echocardiography in patients with MD and DMD. 
Materials and methods
The data for the present study were collected at the Department 
of Pediatrics of Yonsei University College of Medicine, Gangnam 
Severence Hospital (Seoul, Korea). All of the research protocols 
were approved by the Institutional Review Board of Yonsei Uni­
versity Severance Hospital (IRB No. 3­2013­0201). All of the sub­
jects or guardians provided written informed consent, if required.
1. Subjects
One hundred and thirty­two pediatric patients who were diag­
nosed with MD and DMD between January 2010 and March 2013 
were included in this study. There were 90 cases of MD and 42 
patients with DMD. The ages of the patients ranged from 2.5 to 
18.5 years. All of the patients were referred from the Division 
of Pediatric Neurology or Rehabilitation Medicine for routine 
cardiac evaluation upon admission. We excluded clinically un­
stable patients who had fever, severe pain, shock, hypoxemia, 
sepsis, or intractable seizures, because these conditions can alter 
hemodynamic status. All the subjects were within normal blood 
pressure at the time of echocardiography.
Patients with MD were diagnosed by pediatric neurology 
specialists. Along with MD score12), muscle biopsies were obtained 
from all of the patients to diagnose light and electron microscopic 
changes and enzyme activity assessments or mitochondrial gene 
assays were performed13).
The diagnosis of DMD was also confirmed by specialized neu­
rologists. Patients were required to meet the European Neuromu­
scular Center criteria. Eligibility also required an absence of 
dystrophin in the muscle biopsy6). Mutation of the dystrophin 
gene was detected by genetic analysis of dystrophin14).
All of the basic demographic characteristics and additional 
specific data were listed for the subjects, including age at echo­
cardiography, the age of onset for the first symptom (prominent 
weakness of motor function or delay of neurological development), 
family history (any type of myopathies within second­degree 
relatives), assisted respiratory status with mechanical ventilator, 
wheelchair­bound, mental retardation, moderate degree scoliosis 
(Cobb angle over 25 degrees, before surgery if operated), previously 
diagnosed cardiopathy, or cardiac medication. Patient's height was 
measured on the examination table and weight on the bed scale 
or the wheelchair scale if needed. Laboratory tests included levels 
of aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), creatine kinase (CK), and creatine kinase­MB (CK­MB). 
Arterial blood gas (pH and partial CO2) was examined around the 
time that echocardiography was performed.
2. Echocardiographic parameters
All the transthoracic echocardiographic measurements were 
performed by experienced operators. Two echocardiographic 
systems were used: the Siemens ultrasound system ACUSON 
SC1000 and the GE echocardiography system Vivid 7. All of 
the patients were examined from the parasternal long axis, the 
parasternal short axis and the apical 4­chamber views. M­mode 
measurements were performed in parasternal short axis view at 
papillary muscle level, and the mitral inflow velocities were detected 
at the tips of the mitral leaflets with pulsed wave Doppler. Tissue 
Doppler velocities were measured at the level of the mitral 
septal annulus. All measurements were performed over 3 times 
and averaged values were used. Pulse rate (PR) was checked 
with electrocardiograph (ECG) at the same time. In M­mode 
measurement, the following structural values were assessed: 
interventricular septal thickness (IVSd) and LV posterior wall 
thickness at diastolic phase (LVPWd), interventricular septal 
thickness (IVSs) and LV posterior wall thickness at systolic phase 
(LVPWs), LV end diastolic dimension (LVEDD) and end systolic 
dimension (LVESD). The mitral deceleration times, early (E) to 
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late (A) ventricular filling velocities were checked by pulsed wave 
Doppler. The mitral annulus early diastolic velocity (Ea), late diastolic 
velocity and systolic peak velocity were gained through tissue 
Doppler signals from the medial side of the mitral annulus. E/A 
ratio and E/Ea ratio were derived from these Doppler findings.
3. Various equations in this study
Body weight and height were used to calculate body mass index 
(BMI).
The calculated BMI were converted to BMI­for­age z  scores 
using a growth chart that included the lambda­mu­sigma (LMS) 
parameters of the Centers for Disease Control and Prevention.
Lean body mass (LBM) was deduced by validated sex­specific 
predictive equations that excluded race15).
In male: ln (LBM)=–2.8990+(0.8064×ln [height])+(0.5674×ln 
[weight])+(0.0000185×[weight]2)–(0.0153×[BMIz]2)+(0.0132×age)
In female: ln (LBM)=–3.8345+(0.954×ln [height])+(0.6515×ln 
[weight]) – (0.0102×[BMIz]2)
BSA was calculated by the Mosteller method.
LV end­diastolic volume (LVEDV) and LV end­systolic volume 




Ejection fraction (EF) was calculated from the Teichholz formula.
EF (%)=100×(LVEDV–LVESV)/LVEDV
The relative wall thickness (RWT) was calculated as a ratio of 
wall thickness to inner cavity size.
RWT=2×LVPWd/LVEDD
LV mass was calculated by the Devereux equation17).
LV mass (g)=0.8×1.04×([LVEDD+IVSd+LVPWd]3–[LVEDD]3)+0.6
Stroke volume (SV) was derived from the Teichholz methods 
and cardiac output (CO) was deduced from SV.
SV (mL/beat)=LVEDV–LVESV
CO (L/min)=SV×PR/1000
The allometric equations of SV and CO, established for children 
and adolescents by the same Teichholz method, were applied for 
comparison18). The equations were:
SV (mL/beat)=28.11×(height)1.45
CO (L/min)=2.629×(height)0.92.
To normalize SV and CO for variation in body size, stroke volume 
index (SVI) and cardiac index (CI) were introduced, dividing SV 
and CO by BSA respectively.
4. Normalizing LV mass for variation in body size 
LV mass index (LVMI) is commonly used to normalize LV mass 
to body size in adult. In this study, LVMI was defined as:
LVMI (g/m2.7) = LV mass / (height)2.7.
Previous studies demonstrated that old methods for normalizing 
LV mass, such as LVMI, have some limitations, especially for 
children or adolescents, because of a residual correlation with 
body size11). To resolve this problem, we introduced the lambda 
mu sigma (LMS) method. LV mass­for­height z score and LV mass­ 
for­LBM z score were generated from the L, M, and S values. 
These scores correspond to the individual’s height and LBM, 
respectively11,19).
The reference data for the LMS tables were obtained from a 
prior research study conducted at Boston Children’s Hospital20). 
LV mass­for­LBM z score could not be calculated for all subjects, 
because LBM could not be estimated for children younger than 
five years old15). Thus, the LMS data corresponding to LBM were 
unavailable for LBM values less than 13 kg19).
5. Statistical analysis 
We analyzed the data with the SAS ver. 9.2 (SAS Institute Inc., 
Cary, NC, USA). We compared the parameters of two groups by 
Student t­test or Chi­square test. We used paired t­test for com­
paring two scores in a group. Pearson correlation coefficient was 
applied to analyze relations between two values. Statistical signi­
ficance was determined as P<0.05.
Results
1. Subject characteristics 
The clinical characteristics and laboratory findings are presented 
in Table 1. The ages of the 90 MD and 42 DMD patients were 
differently distributed, and the average ages were 8.4 and 14.3 
years, respectively (P<0.001). The percentages of male patients 
were 58.9% and 100%, respectively (P<0.001). Patients with MD 
showed an earlier onset for symptoms than those with DMD (2.5 
years vs. 3.7 years; P=0.018). The BMIz of the two groups were 
evenly dropped far below zero. A relatively larger percentage of 
DMD patients received assistance from mechanical ventilators 
(54.8%), and mental retardation was prominent in MD (87.8%). 
The percentages of patients who were wheelchair­bound were 
high for those with MD (73.3%) and DMD (88.1%). Moderate 
scoliosis was obvious in DMD group (50.0%) and most of them 
had corrected by previous operations (81.0%).
The enzyme activity assessments revealed mitochondrial 
respiratory complex (MRC) deficiency in 74 patients with MD 
(82.2%). Sixty­one patients were MRC I deficiency, one was MRC 
II and 10 were MRC IV. Several cardiac diseases were previously 
confirmed in patients with MD, including two hypertrophic cardio­
myopathies (HCMP), one premature ventricular complex, one 
Wolff­Parkinson­White syndrome, and one atrial septal defect 
with patch repair status. Among the patients with DMD, one 
dilated cardiomyopathy, two hypokinesias of the left ventricle, 
one dextrocardia, and one severe bradycardia were found. 
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mass­for­LBM z scores were also decreased in MD (–0.94±1.67, 
P<0.001) and DMD (–0.58±1.63, P=0.038). The distributions of 
these z scores are presented in Fig. 1. There were no significant 
differences between LV mass­for­height z scores and LV mass­
for­LBM z scores (–0.72 vs. –0.79, P=0.448) with a highly significant 
correlation (R=0.813, P<0.001).
Cardiac medications, such as digoxin, beta blockers, dopamine, 
angiotensin converting enzyme inhibitors, or diuretics were 
frequently prescribed for DMD patients (23.8%). Abnormal ECG 
findings were found in patients with DMD (78.6%). Laboratory 
values for AST, ALT, CK, and CK­MB were prominently elevated 
in DMD compared to MD. Arterial blood gas analysis showed 
reasonable levels of pH and pCO2, confirming the absence of 
systemic hypoxemia or acidosis in both groups.
2. LV mass-for-height z score and LV mass-for-LBM z score 
Echocardiographic findings are shown in Table 2, and calculated 
LV masses and transformed z scores are presented in Table 3. 
The average LV mass­for­height z scores were decreased below 
zero, suggesting atrophic changes in LV mass in patients with 
MD (–1.02±1.52, P<0.001) or DMD (–0.82±1.61, P=0.002). LV 
Table 1. Demographic characteristics and laboratory findings of patients 
with MD or DMD
Characteristic MD (n=90) DMD (n=42) P value
Male sex 53 (58.9) 42 (100) <0.001
Age (yr) 8.4±3.8 14.3±2.9
Onset (yr) 2.5±3.1 3.7±1.9 0.018
Duration of morbidity (yr) 5.8±2.9 10.6±3.4
Height (m) 1.21±0.22 1.52±0.13
Weight (kg) 25.3±14.9 42.5±15.8
BMI (kg/m2) 15.9±3.9 18.1±5.5
BMIz –1.21±2.2 –1.63±2.90 0.351
LBM* (kg) 19.8±11.4 29.8±11.9
BSA (m2) 0.90±0.33 1.32±0.29
Family history 4 (4.4) 7 (16.7) 0.055
Assisted respiration 7 (7.8) 23 (54.8) <0.001
Wheelchair-bounded 66 (73.3) 37 (88.1) 0.057
Mental retardation 79 (87.8) 6 (14.3) <0.001
Moderate scoliosis 2 (2.2) 21 (50.0)† <0.001
Diagnosed cardiopathy 6 (6.7) 4 (9.5) 0.567
Cardiac medication 5 (5.6) 10 (23.8) 0.002
Abnormal ECG 31 (34.4) 33 (78.6) 0.001
AST (U/L) 29±13 59±42 <0.001
ALT (U/L) 20±16 76±72 <0.001
CK (U/L) 178±435 2,361±2,769 <0.001
CK-MB (U/L) 4.8±14.3 47.0±56.6 <0.001
pH 7.40±0.6 7.41±0.3
pCO2 (mmHg) 34.4±8.8 35.6±3.8
Values are presented as number (%) or mean±standard deviation.
MD, mitochondrial disease; DMD, Duchenne muscular dystrophy; BMI, body 
mass index; BMIz, BMI-for-age z score; LBM, lean body mass; BSA, body 
surface area; ECG, electrocardiograph; AST, aminotransferase; ALT, alanine 
amin otransferase; CK, creatine kinase; CK-MB, creatine kinase-MB; pCO2, 
partial CO2
*The equations indicated for patients aged ≥5 years were used. †Mild scoliosis 
corrected by previous surgery (81.0%) was included.
Table 2. Echocardiographic measurements and myocardial values in 
patients with MD or DMD
Variable MD (n=90) DMD (n=42) P value
Pulse rate (beat/min) 99±20 91±15
IVSd (cm) 0.67±0.15 0.76±0.14
LVPWd (cm) 0.65±0.15 0.74±0.11
IVSs (cm) 0.88±0.18 0.94±0.16
LVPWs (cm) 0.91±0.19 0.98±0.14
LVEDD (cm) 3.44±0.69 4.29±0.56
LVESD (cm) 2.16±0.50 3.03±0.59
DT (msec) 118±30 136±42
Ea (cm/sec) 13.2±2.2 11.6±3.4
Aa (cm/sec) 7.2±1.5 6.1±1.7
Sa (cm/sec) 8.5±1.7 7.8±2.0
EF (%) 68±7 57±10 <0.001
RWT 0.38±0.09 0.35±0.08 0.028
E/A ratio 1.78±0.41 1.82±0.46 0.604
E/Ea ratio 7.47±1.23 7.76±1.82 0.286
SV (mL/beat) 35.1±17.2 46.6±12.9
CO (L/min) 3.3±1.3 4.2±1.3
SVI (mL/beat/m2) 38.2±8.7 36.1±9.5 0.212
CI (L/min/m2) 3.7±0.9 3.3±0.9 0.012
Values are presented as mean±standard deviation. 
MD, mitochondrial disease; DMD, Duchenne muscular dystrophy; IVSd and 
LVPWd, interventricular septal thickness and left ventricular posterior wall 
thickness during the diastolic phase; IVSs and LVPWs, interventricular septal 
thickness and left ventricular posterior wall thickness during the systolic phase; 
LVEDD, left venticular end diastolic dimension; LVESD, left ventricular end 
systolic dimension; DT, deceleration time; Ea and Aa, early and late diastolic 
velocities of the mitral annulus; Sa, systolic peak velocity of the mitral annulus; 
EF, ejection fraction; RWT, relative wall thickness; E/A ratio, ratio of early to late 
mitral filling velocity; E/Ea ratio, ratio of early mitral filling velocity to early dia-
stolic mitral annular velocity; SV, stroke volume; CO, cardiac output; SVI, stroke 
volume index; CI, cardiac index.
Table 3. LV mass, LVMI, and LV mass z scores in patients with MD or DMD
Variable MD (n=90) DMD (n=42) P value
LV mass (g)   61.7±37.2   97.8±29.1 
LVMI (g/m2.7)   35.1±10.4   32.0±10.3 0.112
LV mass-for-height z score –1.02±1.52 –0.82±1.61 0.477
LV mass-for-LBM z score* –0.94±1.67 –0.58±1.63 0.309
Values are presented as mean±standard deviation.
LV, left ventricular; LVMI, LV mass index; MD, mitochondrial disease; DMD, 
Duchenne muscular dystrophy; LBM, lean body mass.
*Patients aged <5 years or with a LBM of <13 kg were excluded.
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3. Functional evaluation from echocardiographic data 
The functional parameters derived from echocardiographic data 
are shown in Table 2. The pulse rates were mostly in reference 
ranges21), but the majority of them was above the median levels 
(72.0%). The EF in patients with MD were adequate22), whereas 
those of DMD were around the lower limit (68% vs. 57%, P<0.001). 
The abnormal EF below 50% were observed in 11 DMD patients 
(26.2%) and one MD patient (1.1%). RWT were slightly higher in 
MD compared with DMD (0.38 vs. 0.35, P=0.025), although RWT 
values were within the normal range23). E/A and E/Ea ratios were 
within normal limits24) and no differences were found between 
MD and DMD. The estimated SV values were relatively decreased 
from allometric SV in MD (35.1 mL/beat vs. 37.3 mL/beat, P= 
0.048) and DMD (46.6 mL/beat vs. 51.7 mL/beat, P=0.016). On 
the contrary, there were lack of significant differences between 
estimated CO and allometric CO in MD (3.3 L/min vs. 3.1 L/min, 
P=0.118) and DMD (4.2 L/min vs. 3.9 L/min, P=0.092).
4. Correlations between LV mass-for height z score and other 
parameters
This study also confirmed if other data available for patients 
correlated with LV mass­for­height z score (Table 4). BMIz sug­
gested positive correlation with LV mass­for­height z score in both 
groups, although duration of morbidity did not. RWT values for 
A B 
Fig. 1. (A) The distributions of the left ventricular (LV) mass-for-height z scores of both patients with MD 
and those with DMD show significantly below-normal LV masses relative to their heights. (B) The distri-
butions of the patients’ LV mass-for-LBM z scores also show significantly below-normal LV masses relative 
to their LBMs. LBM, lean body mass; MD, mitochondrial disease; DMD, Duchenne muscular dystrophy.
A B z z 
Fig. 2. The distributions of the stroke volume index (SVI) (A) and cardiac index (CI) (B) according to the 
left ventricular (LV) mass-for-height z scores correlate significantly in patients with MD or DMD. The 
straight and dotted lines represent the regression lines for patients with MD and DMD, respectively. MD, 
mitochondrial disease; DMD, Duchenne muscular dystrophy.
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growing children. We introduced the LV mass­for­height z score 
based on LMS data from another echocardiographic study, because 
typical indexation methods were not suitable for pediatric pop­
ulations11). Although the influence of body size on LV mass was 
minimized by this scoring system, there were other problems 
that remained. The differences in heart size due to the effects of 
gender, ethnicity, race, and body weight could not be adequately 
corrected with the LV mass­for­height z score. Previous studies 
demonstrated that LBM was the most powerful determinant of 
LV mass compared with gender, race, weight, and other para­
meters26). The LV mass­for­LBM z score could also be calculated 
from the LMS table provided in another study19). This might be 
a more accurate method than using the z score based on height, 
but the complex calculation and age limitation of LBM should 
be carefully considered.
Our study demonstrated either the LV mass­for­height z score 
and the LV mass­for­LBM z score indicate reduction of LV mass 
beyond the effect of body size. A sufficient correlation between 
them satisfied the availability of the z score derived from height 
in place of LBM. Although the influence of disease duration on 
those z scores was not effectively proven in our study, BMIz 
showed significant correlations instead. Most of our patients had 
relatively small heights and low weights for age. Decreased BMIz 
might represent growth failure or muscle wasting in children 
with MD or DMD27,28). But LV reduction was beyond a reasonable 
proportion to the effect of bodily loss. LV masses were below the 
demand of body size in our patients.
The estimated SV values were below the standards but the 
estimated CO values were along with expected values probably 
by rapid PR in our patients. We should carefully consider a proper 
reason for the maintenance of CO despite their lower physical 
activities. The basal metabolic rates in MD and DMD might be 
increased with ATP synthesis reduction or protein catabolism 
increment29,30). As CO are determined by the basal metabolic rate 
as well as physical activity31), and SV are limited by decreased 
LV size, the myocardium would be forced to beat more. At this 
point, we can imagine the myocardium encountered two major 
threats: mass reduction and overwork. Therefore, the cardiac 
muscles in MD or DMD could be under chronic fatigue similar to 
other skeletal muscles32,33). 
The parallel tendencies of SVI or CI relative to LV mass z scores 
also might be crucial, because the correlations imply myocardial 
reduction progresses with deterioration of systolic function. These 
results are comparable to measurements of diastolic function 
with E/A ratio or E/Ea ratio. They were grossly in normal ranges 
and had no correlations with LV mass z scores. Thus, our results 
indicate an essential role for LV mass in sustaining sufficient systolic 
function for body size. The atrophic change of myocardium and 
its functional influence have already been suggested in some 
studies of DMD or the paralyzed patients previously9,10). They 
the two groups did not show significant correlations with LV 
mass­for­height z score. Meanwhile, SVI and CI showed overall 
positive correlations with LV mass­for­height z score in MD 
(SVI: R=0.528, P<0.001; CI: R=0.370, P<0.001) and DMD (SVI: 
R=0.369, P=0.016; CI: R=0.406, P=0.008) (Fig. 2). The same 
correlations were seen with LV mass­for­LBM z score in MD 
(SVI: R=0.600, P<0.001; CI: R=0.425, P=0.001) and DMD (SVI: 
R=0.410, P=0.012; CI: R=0.436, P=0.007). The presence of other 
baseline characters such as family history, assisted respiration, 
wheelchair­bound, mental retardation, moderate scoliosis, pre­
viously diagnosed cardiac disease, cardiac medication, and ECG 
abnormalities did not make differences with LV mass­for­height 
z score or LV mass­for­LBM z score.
Discussion
According to previous studies, the most common cardiac in­
volvements in MD are HCMP, which occur in approximately 20 
% of MD patients. The cardiomyopathies associated with MD are 
usually diagnosed early in infancy, and rapidly progress to death 
before the age of two2,7). Meanwhile, cardiac dysfunctions in 
DMD are usually expressed as dilated cardiomyopathies6,8). Most 
of them present during the teen years, and their lifetime mor­
bidity is about 90% with a 20% mortality rate25). As discussed 
above, investigations into the cardiopathologic changes that 
occur in MD and DMD have focused mainly on LV hypertrophy 
or dilation. Besides, an assumption of the steady shrinkage of 
heart could be possible, considering the progressive loss of other 
body components. Thus, we performed this study to confirm the 
structural and functional changes of the myocardium.
The first obstacle was normalizing LV mass to body size in 
Table 4. Correlations between the measurements and the LV mass-for-
height z score
Variable
MD (n=90) DMD (n=42)
Coefficient (r) P  value Coefficient (r) P  value
Duration of morbidity 0.167 0.116 –0.018 0.908
BMIz 0.377 <0.001 0.330 0.033
EF (%) –0.032 0.767 –0.220 0.162*
RWT 0.167 0.116 –0.089 0.575
E/A ratio 0.031 0.774 0.205 0.198
E/Ea ratio 0.018 0.869 –0.310 0.048
SVI (mL/beat/m2) 0.528 <0.001* 0.369 0.016*
CI (L/min/m2) 0.370 <0.001* 0.406 0.008*
LV, left ventricular; MD, mitochondrial disease; DMD, Duchenne muscular 
dystrophy; BMIz, body mass index-for-age z score; EF, ejection fraction; RWT, 
relative wall thickness; E/A ratio, ratio of early to late mitral filling velocity; E/Ea 
ratio, ratio of early mitral filling velocity to early diastolic mitral annular velocity; 
SVI, stroke volume index; CI, cardiac index; LBM, lean body mass.
*Values significantly correlated with the LV mass-for-LBM z score (P<0.05).
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demonstrated the reduction of cardiac mass in their patients, and 
proportionally decreased systolic function by increased afterload 
secondary to wall thinning. These findings are similar with the 
results of our study in MD as well as DMD. With an improved 
methodology of echocardiographic analysis, we reassure the 
myocardial atrophy and systolic influences in MD and DMD. If 
the metabolic demands are increased by severely ill conditions, 
the atrophied myocardium might fall into more prominent dys­
function.
Pathologic changes of myocardium should be characterized by 
wall­to­cavity ratio basically. One obesity study demonstrated 
the shared variability among body weight, LV mass and RWT34), 
and the study on DMD showed LV mass atrophy was driven 
by reduced wall thickness rather than cavity diameter10). Thus, 
myocardial thinning was presumed to initiate mass reduction 
accordingly in this study. Against the expectation, RWT was 
not significantly correlated with LV mass z score, and did not 
deviate from normal limits identifying the possibility of equally 
diminished LV wall thickness and inner cavity diameter. The 
exact explanation for the disparity could not be given in this 
cross­sectional study. We can only suggest that the myocardial 
changes might be from different pathologic processes between 
MD and DMD for their different RWT. Or a further longitudinal 
study could determine common dynamics of LV wall changes.
Our study has some limitations. First, even though the number 
of subjects was large, patients were confined to one medical center 
in our institution. This limitation might have resulted in the 
lower incidences of cardiac involvements against as reported. 
Thus, multicentered, multiracial studies should be conducted in 
the future. Second, the analysis for the echocardiographic data had 
been performed with the single examination on each patient. 
The investigation of myocardial atrophy should be required 
to analyze sequential changes over time meticulously. The 
possibility of restoration of LV mass needs to be identified to 
help improve cardiac function in patients with MD and DMD. 
Nevertheless, this study provides better insights into the myo­
cardial atrophy and its hemodynamic influences in MD and DMD.
In conclusion, we estimated LV mass z scores using M­mode 
echocardiography to demonstrate the presence of LV atrophy in 
MD and DMD patients. The cardiac reduction might be in a close 
association with decreased BMI. LV mass insufficiency for body 
size might indicate deterioration of systolic function in patients 
with MD and DMD.
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